Eli Lilly's LLY short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

Novo's Ozempic is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, while Wegovy is primarily prescribed for obesity care. In the same vein, Lilly's Mounjaro is approved ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro ... "FDA is aware that some patients and health care professionals may look to unapproved ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.’s LLY weight loss drug Zepbound for treating sleep apnea What Happened: The FDA’s decision makes Zepbound the first ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. With the FDA’s green light on Friday, Lilly’s dual ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first ...

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat ...

and others are completely redefining how care is provided to patients with diabetes or in need of weight management. Here are some big moves Lilly is making to strengthen its position in the ...